Company profile YMAB

Y-Mabs Therapeutics Inc
y-mabs is late-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. the company has a broad and advanced product pipeline, including 2 pivotal-stage product candidates - naxitamab and omburtamab - which target tumors that express gd2 and b7-h3, respectively. our miss...ion is to become the world leader in developing antibody-based cancer products that address clear unmet needs in pediatric oncology. with the right partnerships and collaboration, we envision expanding our capabilities to treat adults - changing the course of cancer and its outcome. Show More
Quarter analysis & expected interest

There is not enough data for Y-mAbs Therapeutics -stock -company to provide analysis

Correlation between past revenue and Y-mAbs Therapeutics -stock -company search interest

There is not enough data for Y-mAbs Therapeutics -stock -company to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Y-mAbs Therapeutics -stock -company to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Y-mAbs Therapeutics login to provide analysis

Correlation between past revenue and Y-mAbs Therapeutics login search interest

There is not enough data for Y-mAbs Therapeutics login to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Y-mAbs Therapeutics login to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Y-mAbs Therapeutics DANYELZA to provide analysis

Correlation between past revenue and Y-mAbs Therapeutics DANYELZA search interest

There is not enough data for Y-mAbs Therapeutics DANYELZA to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Y-mAbs Therapeutics DANYELZA to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Y-mAbs Therapeutics GD2-SADA to provide analysis

Correlation between past revenue and Y-mAbs Therapeutics GD2-SADA search interest

There is not enough data for Y-mAbs Therapeutics GD2-SADA to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Y-mAbs Therapeutics GD2-SADA to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Y-mAbs Therapeutics Omburtamab to provide analysis

Correlation between past revenue and Y-mAbs Therapeutics Omburtamab search interest

There is not enough data for Y-mAbs Therapeutics Omburtamab to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Y-mAbs Therapeutics Omburtamab to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Y-mAbs Therapeutics huB7-H3 to provide analysis

Correlation between past revenue and Y-mAbs Therapeutics huB7-H3 search interest

There is not enough data for Y-mAbs Therapeutics huB7-H3 to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Y-mAbs Therapeutics huB7-H3 to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Y-mAbs Therapeutics pipeline to provide analysis

Correlation between past revenue and Y-mAbs Therapeutics pipeline search interest

There is not enough data for Y-mAbs Therapeutics pipeline to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Y-mAbs Therapeutics pipeline to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Y-mAbs Therapeutics headquarters to provide analysis

Correlation between past revenue and Y-mAbs Therapeutics headquarters search interest

There is not enough data for Y-mAbs Therapeutics headquarters to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Y-mAbs Therapeutics headquarters to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Y-mAbs Therapeutics cancer treatment to provide analysis

Correlation between past revenue and Y-mAbs Therapeutics cancer treatment search interest

There is not enough data for Y-mAbs Therapeutics cancer treatment to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Y-mAbs Therapeutics cancer treatment to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Y-mAbs Therapeutics pediatric cancer treatment to provide analysis

Correlation between past revenue and Y-mAbs Therapeutics pediatric cancer treatment search interest

There is not enough data for Y-mAbs Therapeutics pediatric cancer treatment to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Y-mAbs Therapeutics pediatric cancer treatment to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Useful links and data for YMAB
Earnings date: 2024-02-22 After close
Company name: Y-Mabs Therapeutics Inc
Sector: Professional, Scientific, and Technical Services
Company's website
Hypercharts
Yahoo Finance
MarketWatch
StockTwits
SEC Filings
SwaggyStocks
Latest articles

2025-09-26T08:30:07-04:00

SEC
15-12G Form - Securities registration termination [Section 12(g)] - Y-mAbs Therapeutics, Inc. (0001722964) (Filer)

2025-09-19T06:00:15-04:00

SEC
4 Form - Statement of changes in beneficial ownership of securities - Y-mAbs Therapeutics, Inc. (0001722964) (Issuer)

2025-09-18T21:39:55-04:00

SEC
4 Form - Statement of changes in beneficial ownership of securities - Y-mAbs Therapeutics, Inc. (0001722964) (Issuer)

2025-09-18T21:29:01-04:00

SEC
4 Form - Statement of changes in beneficial ownership of securities - Y-mAbs Therapeutics, Inc. (0001722964) (Issuer)

2025-09-18T21:27:10-04:00

SEC
4 Form - Statement of changes in beneficial ownership of securities - Y-mAbs Therapeutics, Inc. (0001722964) (Issuer)

2025-09-18T21:24:36-04:00

SEC
4 Form - Statement of changes in beneficial ownership of securities - Y-mAbs Therapeutics, Inc. (0001722964) (Issuer)

2025-09-18T21:12:33-04:00

SEC
4 Form - Statement of changes in beneficial ownership of securities - Y-mAbs Therapeutics, Inc. (0001722964) (Issuer)

2025-09-18T21:09:41-04:00

SEC
4 Form - Statement of changes in beneficial ownership of securities - Y-mAbs Therapeutics, Inc. (0001722964) (Issuer)

2025-09-18T21:08:14-04:00

SEC
4 Form - Statement of changes in beneficial ownership of securities - Y-mAbs Therapeutics, Inc. (0001722964) (Issuer)

2025-09-18T21:06:30-04:00

SEC
4 Form - Statement of changes in beneficial ownership of securities - Y-mAbs Therapeutics, Inc. (0001722964) (Issuer)

2025-09-18T21:03:47-04:00

SEC
4 Form - Statement of changes in beneficial ownership of securities - Y-mAbs Therapeutics, Inc. (0001722964) (Issuer)

2025-09-18T21:01:12-04:00

SEC
4 Form - Statement of changes in beneficial ownership of securities - Y-mAbs Therapeutics, Inc. (0001722964) (Issuer)

2025-09-18T20:59:46-04:00

SEC
4 Form - Statement of changes in beneficial ownership of securities - Y-mAbs Therapeutics, Inc. (0001722964) (Issuer)

2025-09-17T00:15:04-04:00

SEC
EFFECT Form - Notice of Effectiveness - Y-mAbs Therapeutics, Inc. (0001722964) (Filer)

2025-09-16T09:10:19-04:00

SEC
S-8 POS Form - Securities to be offered to employees in employee benefit plans, post-effective amendments - Y-mAbs Therapeutics, Inc. (0001722964) (Filer)